Qilian International Holding Group (Qilian International Holding Group) Gross Margin % : -3.14% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Qilian International Holding Group Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Qilian International Holding Group's Gross Profit for the six months ended in Sep. 2023 was $-0.54 Mil. Qilian International Holding Group's Revenue for the six months ended in Sep. 2023 was $17.31 Mil. Therefore, Qilian International Holding Group's Gross Margin % for the quarter that ended in Sep. 2023 was -3.14%.

Warning Sign:

Qilian International Holding Group Ltd gross margin has been in long-term decline. The average rate of decline per year is -24.9%.

The historical rank and industry rank for Qilian International Holding Group's Gross Margin % or its related term are showing as below:

QLI' s Gross Margin % Range Over the Past 10 Years
Min: 3.77 Med: 15.01 Max: 21
Current: 3.77

During the past 7 years, the highest Gross Margin % of Qilian International Holding Group was 21.00%. The lowest was 3.77%. And the median was 15.01%.

QLI's Gross Margin % is ranked worse than
94.55% of 991 companies
in the Drug Manufacturers industry
Industry Median: 46.77 vs QLI: 3.77

Qilian International Holding Group had a gross margin of -3.14% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Qilian International Holding Group was -24.90% per year.

Qilian International Holding Group Gross Margin % Historical Data

The historical data trend for Qilian International Holding Group's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qilian International Holding Group Gross Margin % Chart

Qilian International Holding Group Annual Data

Trend

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Gross Margin %

Get a 7-Day Free Trial

21.00

15.07

9.88

9.60

3.77

Qilian International Holding Group Semi-Annual Data
	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Gross Margin %	Get a 7-Day Free Trial								5.70	10.91	8.32	7.87	-3.14

Competitive Comparison of Qilian International Holding Group's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Qilian International Holding Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qilian International Holding Group's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Qilian International Holding Group's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Qilian International Holding Group's Gross Margin % falls into.

Qilian International Holding Group Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Qilian International Holding Group's Gross Margin for the fiscal year that ended in Sep. 2023 is calculated as

Gross Margin % (A: Sep. 2023 )	=	Gross Profit (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	1.8	/	46.471
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(46.471 - 44.72)	/	46.471
	=	3.77 %

Qilian International Holding Group's Gross Margin for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )	=	Gross Profit (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-0.5	/	17.308
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(17.308 - 17.851)	/	17.308
	=	-3.14 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Qilian International Holding Group (NAS:QLI) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Qilian International Holding Group had a gross margin of -3.14% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Qilian International Holding Group Gross Margin % Related Terms

Thank you for viewing the detailed overview of Qilian International Holding Group's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Qilian International Holding Group (Qilian International Holding Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Qilian International Holding Group Ltd (NAS:QLI) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jiuquan Economic and Technological Development Zone, Gansu Province, Jiuquan, CHN, 735000

Website

http://ir.qlsyy.net

Qilian International Holding Group Ltd is a pharmaceutical and chemical company. The company is engaged in the development, manufacture, marketing, and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers. It operates through three segments namely, Oxytetracycline and Licorice products and TCMD; Fertilizer; and Heparin products and Sausage casing. Oxytetracycline and Licorice products and TCMD segment generates majority of the revenue.